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Abstract
Background: Despite recent progress in the identification of genetic and molecular alterations in
prostate cancer, markers associated with tumor progression are scarce. Therefore precise
diagnosis of patients and prognosis of the disease remain difficult. This study investigated novel
molecular markers discriminating between low and highly aggressive types of prostate cancer.
Results: Using 52 microdissected cell populations of low- and high-risk prostate tumors, we
identified via global cDNA microarrays analysis almost 1200 genes being differentially expressed
among these groups. These genes were analyzed by statistical, pathway and gene enrichment
methods. Twenty selected candidate genes were verified by quantitative real time PCR and
immunohistochemistry. In concordance with the mRNA levels, two genes MAP3K5 and PDIA3
exposed differential protein expression. Functional characterization of PDIA3  revealed a pro-
apoptotic role of this gene in PC3 prostate cancer cells.
Conclusions: Our analyses provide deeper insights into the molecular changes occurring during
prostate cancer progression. The genes MAP3K5 and PDIA3 are associated with malignant stages of
prostate cancer and therefore provide novel potential biomarkers.
Background
Prostate cancer is the most frequent cancer diagnosed in
men (20.3% of the total), followed by lung (17.2%) and
colorectal cancer (12.8%) [1]. Measuring prostate specific
antigen (PSA) has been a matter of routine to detect pros-
tate cancer, but is insufficient to distinguish between dif-
ferent tumor grades. The Gleason Grading System is
commonly used for histology-based grading of prostate
cancer tissue [2]. Since prostate tumors are often multifo-
cal, the Gleason Score (GS) is the sum of the two most
prevalent tumor patterns, which are graded 1 (CA1) as the
most differentiated and 5 (CA5) as the least differentiated
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pattern of cancerous glands. Other methods for sub-clas-
sification have been described in recent reports [3]. These
indicate that translocations fusing the strong androgen-
responsive gene TMPRSS2 with ERG or other oncogenic
ETS factors may facilitate prostate cancer development. It
has been proposed that the presence or absence of this
genetic rearrangement may be used, much like the
Gleason grading system, as a diagnostic tool to extract
prognostically relevant sub-classifications of this cancer
[4].
The discrimination between different tumor grades is
important with respect to treatment decisions: Currently,
many men who are diagnosed with GS 6 prostate cancer
are often "over"-treated and risk suffering from urinary
and sexual dysfunction [5]. Therefore, it is important to
develop a sensitive and specific diagnostic tool to distin-
guish between different tumor grades. To address this
problem, many groups have recently started to profile
gene expression levels in prostate tumor tissues to identify
deregulated genes during disease progression. However,
although many of these have addressed the question of
molecular differences between normal, tumor, benign
prostatic hyperplasia (BPH), and the putative precursor
lesion prostatic intraepithelial neoplasia (PIN), little is
still known about molecular changes between low- and
high-risk tumors [6-9].
In the present study, we performed microarray-based gene
expression profile analysis of 65 microdissected tissues
comprising 25 samples of GS 6, 27 of GS 8-10 and 13 non
cancerous samples. We sought to identify biological
markers of distinct functional groups for the discrimina-
tion between low- and high-risk tumors. Overall, we
found 20 genes with a significant alteration in expression
between high-risk compared to low-risk tumors. Two of
these genes exhibited Gleason grade associated protein
expression in tumor tissues, which could serve as a valua-
ble diagnostic tool in the future.
Results
mRNA expression analysis revealed large expression 
differences between GS 6 and GS 8-10 tumors
To selectively isolate pure populations of prostate epithe-
lial cancer cells with different Gleason Scores, we first
applied laser-capture microdissection. We monitored the
gene expression levels by hybridization of twice-amplified
RNA to cDNA microarrays representing ~37500 mapped
genes. In total, we hybridized 65 RNA samples derived
from 13 benign and 52 prostate cancer tissue comprising
25 samples with Gleason Score (GS) 6 and 27 samples
with GS 8-10 (Table 1). After quality assessment of micro-
array hybridizations, we subjected gene expression pro-
files to SAM [10]. Numbers of deregulated genes
identified by SAM analyses are summarized in Table 2,
and complete gene lists are provided (see additional file 1
and additional file 2).
For the identification of grade-discriminating genes, we
compared the expression levels of GS 6 with GS 8-10
tumors. SAM analysis revealed 1141 up-regulated and 54
down-regulated non-redundant genes in advanced
tumors (FDR 5%; see additional file 1). For validation, we
compared our data with an independent study from True
and coworkers, who reported 86 genes as deregulated dur-
ing tumor progression from low to high GS [6]. Of these,
we identified 24 genes (28%) which all displayed the
same tendency as in the original report (see additional file
3). Another comparison to the study of Lapointe and cow-
orkers [7], who described 41 genes to be associated to a
higher Gleason score revealed an overlap of six genes
(BGN, COL1A2, COL3A1, PLA2G2A, SPARC, VCAN).
To identify biological processes associated with tumor
progression, we performed gene ontology analysis with
genes differentially regulated between low- and high-risk
tumors. In order to extract highly significant canonical
pathways, each gene symbol was mapped to its corre-
sponding gene object in the IPA Knowledge Base, and net-
works were generated. Significant canonical pathways
were related to actin-mediated processes, e.g. regulation of
Table 1: Characteristics of study population
Stage N = median age
Benign 13 63
GS 6 25/0* 60
GS 8 13/4* 66
GS 9 13/2*
GS 10 1/0*
* matched benign
Table 2: Number of differentially expressed genes (FDR < 5%)
Comparison (SAM test) up down
Normal ↔ Tumor 243 2390
Normal ↔ Tumor (GS6) 463 2016
Normal ↔ Tumor (GS8-10) 454 2001
Tumor (GS6) ↔ Tumor (GS8-10) 1141 54Molecular Cancer 2009, 8:130 http://www.molecular-cancer.com/content/8/1/130
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actin-based motility mediated by Rho-family GTPases (11
of 92 annotated genes, p = 5.23E-03) and actin cytoskele-
ton signaling (19 of 221 annotated genes, p = 1.4E-02). In
addition, various metabolic processes, including oxidative
phosphorylation (22 of 158 annotated genes; p = 8.95E-
06) and protein ubiquitination (19 of 205 annotated
genes; p = 5.6E-03) were deregulated in high-risk tumors.
In order to extract as many genes as possible involved in
apoptotic processes we used two further GO analysis tools
(FatiGO [11] and GOstat [12]) and identified a set of 46
genes associated with apoptosis (GOstat p = 0.00033; see
additional file 4).
Additionally, we compared gene signatures between nor-
mal and tumor tissue, which lead to the identification of
> 2500 deregulated genes (FDR 5%) of which 2390 genes
were down and 243 up-regulated (see additional file 2).
We performed separate SAM analyses between normal
and GS 6 or GS 8-10 and revealed 2016 and 2001 down-
regulated as well as 463 and 454 up-regulated non redun-
dant genes (Table 2). Of these, 1197 genes were deregu-
lated with the same tendency in both tumor groups.
Interestingly, three genes (VCAN, CLK1 and TMEM16G)
revealed opposite expression levels in these comparisons.
VCAN and CLK1 were found to be significantly down-reg-
ulated in GS 6, but up-regulated in high-risk tumors in
comparison to normal tissue. In agreement with these
results, over-expression of VCAN and CLK1 between pri-
mary prostate cancer and metastatic cancer has recently
been described [9]. In contrast TMEM16G, for which the
microarray findings were supported by qRT-PCR data,
showed the opposite trend. TMEM16G was found up-reg-
ulated between normal and GS 6 tissue, but down-regu-
lated between normal and GS 8 as well as between GS 6
and GS 8 tissues. In a recent study, TMEM16G  was
described as a prostate-specific plasma membrane protein
promoting cell-cell contact in the prostate cancer cell line
LNCaP [13].
Validation of selected genes by qRT-PCR
Based on the microarray gene expression differences
between GS 6 and GS 8-10 tumors (see additional file 1),
68 genes were validated in the same cohort via quantita-
tive real time PCR (see additional file 5). B2M  (β2-
microglobulin) was used as a housekeeping gene due to
its even expression in all analyzed patient groups (Figure
1A). We focused on a selection of genes that are linked to
cancer-relevant gene ontology categories like apoptosis,
cell morphology, metabolism and ubiquitylation. For
example, 24/68 selected genes are functionally associated
to apoptosis (see additional file 4).
In the qRT-PCR analysis of the 68 genes, 23 were signifi-
cantly deregulated between low- and high-risk tumors
(Wilcoxon p < 0.1; see additional file 5). Twenty of these
(87%; Table 3) were in concordance with the microarray
Validation of PDIA3 and MAP3K5 mRNA expression via qRT PCR Figure 1
Validation of PDIA3 and MAP3K5 mRNA expression via qRT PCR. (A) The housekeeping gene β-2 microglobulin 
(B2M) was chosen due to its even expression (mean Ct value) in each analyzed group (benign, GS 6 and GS 8-10 tissue). (B, C) 
Mean normalized expression levels (dCt) of GS 6 and GS 8-10 was determined for PDIA3 (B) and MAP3K5 (C). Results showed 
a significant increase of transcript abundance levels in GS 8-10 tumors in comparison to GS 6 tumors.Molecular Cancer 2009, 8:130 http://www.molecular-cancer.com/content/8/1/130
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Table 3: qRT-PCR verified differentially expressed genes between GS 6 and GS 8-10
No. Gene 
symbol
RZPD ID IMAGE ID GO ID GO term Microarray qRT PCR
q-value (%) fold change p-value (%) fold change
1 ANXA5 IMAGp998G1
518
66470 GO:0006916 anti-apoptosis 0.00 1.47 0.10 4.28
2 APLP2 IMAGp998M0
3537
248618 GO:0016021 transmembrane 0.94 1.22 6.10 2.83
3 COL1A2 IMAGp998D0
9597
271448 GO:0001501 skeletal 
development
0.40 1.18 5.12 2.02
4 CRIM1 IMAGp998K1
3587
267780 GO:0016021 transmembrane 0.00 1.20 8.46 3.23
5 ECHS1 IMAGp998L1
2154
32898 GO:0006635 fatty acid beta-
oxidation
2.43 1.18 5.48 1.89
6 HMGB1 RZPDp201F0
834D
6067961 GO:0006915 apoptosis 0.00 1.40 3.25 4.68
7 MAP3K5 IMAGp998O2
2144
28450 GO:0006915 apoptosis 0.17 1.35 6.94 2.98
8 NGFRAP1 IMAGp998O1
6794
347367 GO:0007275 multicellular 
organismal 
development
0.00 1.32 0.59 3.95
9 NPM1 RZPDp202B1
29D
3996837 GO:0006950 response to 
stress
0.00 1.30 2.59 3.07
10 NUB1 RZPDp1096A
0718D
6064678 GO:0006511 ubiquitin-
dependent 
protein 
catabolic 
process
0.64 1.12 5.87 1.62
11 PDIA3 RZPDp1096G
0216D
5561830 GO:0006915 apoptosis 1.29 1.43 3.05 2.40
12 PLA2G2A IMAGp998N1
3665
297804 GO:0006644 phospholipid 
metabolic 
process
0.50 1.75 4.92 3.00
13 ROCK1 RZPDp201C1
129D
5575521 GO:0006915 apoptosis 0.17 1.17 0.00 9.76
14 TEGT RZPDp1096F
101D
160553 GO:0006915 apoptosis 0.00 1.32 0.73 2.77
15 TMEM16G IMAGp998D1
84645
1895393 GO:0016021 transmembrane 0.00 0.66 4.37 0.35
16 TMEM69 IMAGp998I22
653
293085 GO:0016021 transmembrane 3.78 1.08 4.56 2.77
17 TRAF4 RZPDp201H0
728D
5541746 GO:0006915 apoptosis 4.29 1.26 8.58 2.59Molecular Cancer 2009, 8:130 http://www.molecular-cancer.com/content/8/1/130
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results. Thirty-three genes were determined as non-signif-
icant and 12 genes exhibited Ct values below detection
level. Deregulation of the apoptotic process plays a major
role in tumorigenesis and influences therapeutic outcome
[14]. In total, 11 of 20 significantly verified genes are
involved in apoptotic processes (PDIA3,  MAP3K5,
ANXA5, VDAC1, NGFRAP1, TEGT, NPM1, VCP, TRAF4,
HMGB1, and ROCK1). The two genes MAP3K5 and PDIA3
were selected for in-depth analysis because of their associ-
ation to apoptosis and previous findings in cancer studies.
QRT-PCR expression patterns of PDIA3 and MAP3K5 are
given in Figure 1B and 1C.
Immunohistochemistry demonstrates Gleason-grade 
associated protein expression of MAP3K5 and PDIA3
To confirm our data at the protein level, we performed
immunohistochemical analysis of the proteins MAP3K5
and PDIA3 representing the largest functional group
(apoptosis) of validated genes. Specificity of antibodies
was controlled using western blotting (data not shown).
Protein expression levels in tumor tissue samples were
scored according to a 4 point scoring system. Lowest
expression levels of MAP3K5 and PDIA3 proteins were
seen in benign epithelial cells (Figure 2). In agreement
with the transcript analyses, MAP3K5 exhibited a signifi-
cant Gleason grade-associated protein expression (p <
0.01, Wilcoxon signed rank test). Highest expression lev-
els were observed in Gleason pattern 4 regions (mean 1.8)
whereas Gleason pattern 3 (mean 1.2) and Gleason pat-
tern 5 tumor regions (mean 1.19) displayed lower immu-
noreactivity. Of note, we also observed significant protein
overexpression in prostate intraepithelial neoplasia (PIN)
and in regions of inflammation (data not shown), which
is in agreement with the described involvement of
MAP3K5 with inflammation processes. Immunostaining
was observed in the cytoplasm.
18 VCAN RZPDp1096C
062D
201932 GO:0007155 cell adhesion 0.00 1.31 7.06 2.92
19 VCP IMAGp998O1
0119
123873 GO:0006915 apoptosis 1.29 1.18 7.88 2.75
20 VDAC1 IMAGp998D0
8136
129751 GO:0008632 apoptotic 
program
0.00 1.51 0.30 5.41
Table 3: qRT-PCR verified differentially expressed genes between GS 6 and GS 8-10 (Continued)
IHC analysis of Gleason grade-associated protein expression of PDIA3 and MAP3K5 Figure 2
IHC analysis of Gleason grade-associated protein expression of PDIA3 and MAP3K5. Summary of PDIA3 and 
MAP3K5 protein expression quantification in tissue samples. Paraffin tissue sections were stained according to a standard IHC 
protocol using a staining automate and immunoreactivity of the different Gleason patterns identified in each specimen were 
scored by an uropathologist according to a 4 point scale (no - 0, weak - 1, intermediate - 2 and strong - 3 staining). For both 
antigens immunoreactivity was higher in tumors than in benign epithelium in accordance with the gene expression and real-
time PCR data. Within the different tumor patterns staining intensity increased from CA3 to CA4 and decreased in the most 
dedifferentiated CA5 tumor regions. Interestingly, PDIA3 staining intensity in CA 3 regions within GS6 tumors (CA3 CS6) and 
within GS8 tumors (CA3 GS8) differed significantly, whereas this was not observed with MAP3K5. (B: Benign tissue; CA3: 
Gleason pattern 3, CA4: Gleason pattern 4, CA5: Gleason pattern 5).Molecular Cancer 2009, 8:130 http://www.molecular-cancer.com/content/8/1/130
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PDIA3 also showed a grade-associated protein expression
(p < 0.065, Wilcoxon signed rank test; Figure 2). Expres-
sion was significantly increased in tumor cells compared
to benign epithelium. Among different Gleason patterns
in the tumors, Gleason pattern 4 (GP4) showed the high-
est expression level. Interestingly, expression levels of
PDIA3 in Gleason pattern 3 (CA3) seem to depend on the
accompanying Gleason pattern in the tumor. PDIA3
expression was higher in presence of higher Gleason pat-
terns (CA3 in GS 8 tumors, e.g. CA3 associated with CA5;
mean score 1.97) than in tumors with uniform Gleason
pattern 3 (CA3 in GS6 tumors; mean score 1.74). Immu-
nostainings showed cytoplasmic and perinuclear localiza-
tion of PDIA3. In advanced tumors, PDIA3 and MAP3K5
displayed a heterogeneous staining pattern and the vari-
ances of intensity distributions were higher. Representa-
tive pictures of PDIA3 and MAP3K5 in different tissue
regions are shown in Figure 3, where AMACR serves as a
positive control for tumor cells [15].
Decreased apoptotic activity upon knockdown of PDIA3 
in prostate cancer cell lines
MAP3K5 and PDIA3 were found to be proteins associated
with apoptotic processes via pathway analysis. Unlike
MAP3K5, whose pro-apoptotic and inflammatory role in
context of tumorigenesis is well established [16,17], the
function for PDIA3 in apoptosis has been largely unex-
plored. To investigate an apoptosis-related function of
PDIA3 we performed siRNA-based knockdown in the
human prostate cancer cell lines PC3 and LNCaP. 48
hours after siRNA treatment (20 nM or 40 nM) the knock-
down efficiency was determined by qRT-PCR (Figure 4A).
Induction of apoptosis was mediated by three different
stimuli. Staurosporine (STS), Fenretinide (FenR) and Tap-
sigargin (TG) are known to activate apoptosis via distinct
mechanisms [18-20]. Each stimulus activated the apop-
totic pathway reflected by activation of caspase 3 and/or
caspase 7 (Figure 4B). PDIA3 siRNA treatment revealed a
significant decrease of caspase activation in PC3 cells with
all stimuli in comparison to control siRNA treated cells. In
LNCaP cells similar results were obtained, but were only
IHC analysis for the proteins AMACR, MAP3K5 and PDIA3 Figure 3
IHC analysis for the proteins AMACR, MAP3K5 and PDIA3. Representative IHC pictures are shown for AMACR, 
MAP3K5 and PDIA3. AMARC was used as a marker for confirmation of the tumor. MAP3K5 and PDIA3 IHC revealed cyto-
plasmatic localization of both antigens and higher expression in tumors as compared to benign epithelium. Gleason pattern 
CA4 displayed highest staining levels, compared with CA3 (lower midst and right pictures; magnification upper panel: 400×; 
lower panel: 200×).Molecular Cancer 2009, 8:130 http://www.molecular-cancer.com/content/8/1/130
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siRNA mediated knockdown of PDIA3 decreased apoptosis in prostate cancer cell line Figure 4
siRNA mediated knockdown of PDIA3 decreased apoptosis in prostate cancer cell line. (A) Knockdown efficiency 
measured via qRT PCR 48 h after transfection with 20 nM siRNA. (B) PC3 cells were treated with 20 nM scrambled siRNA 
control and PDIA3 siRNA. 48 h after transfection induction of apoptosis was performed with 1 μM Staurosporine (STS), 20 μM 
Fenretinide (FenR) or 1.5 μM Tapsigargin (TG) for 6 and 24 hours. Apoptosis was measured by determining caspase activation 
and compared to untreated control. Bar heights and error bars are means and upper range of triplicate samples relative to 
control treatment. * P < 0.05 (unpaired t-test).Molecular Cancer 2009, 8:130 http://www.molecular-cancer.com/content/8/1/130
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significant after STS induction (data not shown). These
results indicate a novel, pro-apoptotic role for PDIA3 in
prostate cancer cells.
Discussion
Recent studies showed that it is important to include dif-
ferent tumor stages of prostate cancer in gene expression
analyses to be able to find new diagnostic and prognostic
markers [6,8,9]. Here, we generated gene expression pro-
files of tissues from low-risk (GS 6) and high-risk prostate
tumors (GS 8-10) tissues. In contrast to most other pub-
lished studies, all tissue samples were carefully microdis-
sected before RNA isolation. The comparison of these
profiles revealed that both tumor subgroups differ by a
large number of genes, most of which are up-regulated in
high GS tumors. A comparison with another published
data set [6] suggested that these results reflect a general
trend in transcriptional activation in advanced prostate
tumors. However, it cannot be fully ruled out that system-
atic changes introduced by different extents of stromal
cells [8] in the microdissected material as well as two
rounds of RNA amplification contribute to this bias.
Among the detected genes many are involved in path-
ways, which are known to be altered in tumor progression
such as apoptosis, morphologic changes, metabolism,
and ubiquitin-mediated protein degradation. Twenty rep-
resentatives of these processes were verified via qRT-PCR,
and a set of genes discriminating between less and more
aggressive tumor forms was identified. One of the hall-
marks of aggressive cancer is the imbalance between cell
survival and apoptosis. Our gene ontology analysis
revealed that a pronounced number of apoptosis-related
genes exhibited expression changes between low- and
high-risk prostate tumors. Thus, for validation, we
focused our analysis on up-regulated anti-apoptotic genes
and key players of apoptotic signaling and verified the
expression level of 11 selected genes. These data were sup-
ported by the analysis of protein expression levels for
MAP3K5 and PDIA3 by IHC. MAP3K5 and PDIA3 were
also identified in other prostate cancer profiling studies
[6,7,9,21]. MAP3K5 (also known as apoptosis signal-reg-
ulating kinase 1; ASK1) has been widely accepted as one
of the key components regulating reactive oxygen species
(ROS) - induced JNK and p38 activation leading to differ-
entially regulated apoptosis [22]. ROS - dependent activa-
tion of MAP3K5 also plays a critical role in innate
immune responses through production of proinflamma-
tory cytokines [23]. There is considerable evidence sug-
gesting that oxidative stress contributes to the
pathogenesis of prostate cancer [24,25]. Given that mito-
chondria are a major source of reactive oxygen species
(ROS), altered mitochondrial bioenergetics might induce
MAP3K5 over-expression and contribute to the malignant
progression of prostate tumors. In concordance with this
hypothesis, we also found a significant number of dereg-
ulated genes involved in oxidative phosphorylation and
mitochondrial dysfunction.
Like MAP3K5, PDIA3 (protein disulfide isomerase A3) is
a member of the endoplasmatic reticulum stress signaling
pathway also known as unfolded protein response (UPR),
and its expression level increases in response to cellular
stress due to its function as a chaperone [26]. Recently
published data connected PDIA3 to the apoptotic process
and demonstrated an anti-apoptotic effect of PDIA3 in the
melanoma cell line A375 after induction of ER stress [27].
In contrast, our study suggested a decrease of caspase
activity due to down regulation of PDIA3 in prostate can-
cer cell lines. This result suggests that the observed
increase of PDIA3 in this study is most likely due to ele-
vated cellular stress. But besides the role as a chaperone,
PDIA3 might function as a pro-apoptotic protein in the
prostate. Taking our IHC data of PDIA3 into account,
PDIA3 protein concentration decreases significantly in
CA5 compared to CA4 tissues and expression data com-
paring localized with metastatic prostate cancer showed a
down-regulation of PDIA3 [9]. These findings support the
idea that down regulation of PDIA3 might play a role in
late onset of prostate cancer progression. A lack of PDIA3
expression also correlates with increased tumor invasion
and advanced stage of gastric cancer and has therefore
been proposed to be a negative prognostic marker [28].
In addition to its role in the ER stress pathway, PDIA3 has
recently gained attention due to its function as a compo-
nent of the peptide-loading complex of the major histo-
compatibility complex (MHC) class I pathway [29,30]. In
PDIA3 deficient mice this complex is impaired and nega-
tively influences presentation of antigenic peptides. This
may help tumors to escape from immune surveillance by
cytotoxic T cells [31].
The results of our IHC analysis point to a potential use of
PDIA3 as a diagnostic marker: PDIA3 expression of
Gleason pattern 3 tumors is higher in the presence of a
Gleason pattern 5 tumor than in presence of another
Gleason pattern 3 tumor. Additionally, PDIA3  and
MAP3K5 have been found to be significantly (FDR 5%)
up-regulated in tumors harboring a TMPRSS2 - fusion
protein (data not shown). This underlines the opportu-
nity to use PDIA3 and MAP3K5 as discriminating biomar-
kers in respect to histological grading system and gene
arrangement classification.
In summary, this study validated a set of 20 genes, which
discriminated between low and high Gleason grade pros-
tate tumors. These genes comprise important functional
processes well known to be involved in tumor progression
such as apoptosis, morphological changes, metabolismMolecular Cancer 2009, 8:130 http://www.molecular-cancer.com/content/8/1/130
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and others. In addition, we show a grade-associated pro-
tein expression of MAP3K5 and PDIA3. In particular, high
PDIA3 protein levels in Gleason pattern 3 cancers may
indicate the presence of more aggressive tumor foci in the
same tissue and could be of diagnostic value, possibly as
part of a larger molecular signature.
Materials and methods
Tissue specimens
Frozen and paraffin-embedded prostate tissue samples
were obtained from previously untreated patients who
had undergone radical prostatectomy after tumor diagno-
sis in a PSA based screening program performed in Tyrol
by the Department of Urology, Medical University of
Innsbruck [32]. The study was approved by the ethics
committee at the Medical University of Innsbruck. Imme-
diately after surgery, the prostate specimens were cooled
in ice/water and brought to the pathologist who per-
formed a rapid section and isolated a prostate slice that
was embedded in Tissue-Tek OCT Compound (Sakura,
Tokyo, Japan), snap frozen in liquid nitrogen and stored
at -80°C until use. The rest of the prostate was fixed and
paraffin-embedded according to standard procedures.
Tissue microdissection
For isolation of total RNA, frozen sections were stained
with hematoxylin and eosin for pathological analysis and
exact localization of the tumors. Parallel unstained slides
were used for microdissection. These were pre-treated for
1 min in each of the following pre-cooled solutions: 75%
ethanol, RNase-free water, 100% ethanol (twice) and
xylene (twice), and air dried. Laser-capture microdissec-
tion was performed on a Pix Cell II microdissection
microscope (Arcturus, Sunnyvale, CA, USA) using 2,000-
5,000 laser impulses corresponding to approximately 15
000 - 30 000 cells for each sample. Tumor samples were
isolated from a cohort of Gleason score 6 tumors
(Gleason pattern 3) and a group of Gleason score 8 - 10
tumors (Gleason patterns 4 and 5). Benign epithelial cell
samples were microdissected apart from tumor foci from
histopathologically normal regions of the same speci-
mens. After microdissection, total RNA was isolated using
the PicoPure isolation kit (MDC, Sunnyvale, USA) accord-
ing to the protocol of the supplier. Quality control was
done employing the Agilent Bioanalyzer 2100 system
(Agilent Technologies, Waldbronn, Germany).
Microarray analysis
20 ng of RNA isolated from laser-capture microdissected
epithelial prostate cells of tissues from patients who had
undergone radical prostatectomy were subjected to a two-
round amplification using the MessageAmpTM II aRNA
Amplification Kit (Applied Biosystems/Ambion, Austin,
USA). The quality of amplified RNA (aRNA) fragments
was assessed by microcapillary electrophoresis using the
Agilent Bioanalyzer 2100 system. Two micrograms of
aRNA were subjected to microarray hybridization as
described in [33]. Briefly, aRNA was reverse transcribed
using SuperScript II reverse transcriptase (Invitrogen, San
Diego, CA, USA) and labeled with Cy5-dUTP. Each sam-
ple was compared to a common reference (Universal
Human Reference RNA; Stratagene, La Jolla, CA, USA)
labeled with Cy3-dUTP. Hybridizations were done using
the platform Human Unigene3.1 cDNA Array 37.5K v1.0
(NCBI, GEO, GPL3050) representing estimated 22,000
transcripts. Data were analyzed using the GenePix 4.0
software (Axon Instruments, Foster City, USA). Low qual-
ity measurements were excluded from further analysis.
Raw expression values were pre-processed using Array-
Magic [34] and thereby normalized using the VSN
method [35].
Data analysis and data mining
Significance Analysis of Microarrays (SAM) was applied to
identify genes differentially regulated between normal tis-
sue, tumor tissue GS 6 and GS ≥ 8 [10]. A two class
unpaired SAM test with 1000 permutations was used. The
False Discovery Rate (FDR) was set below 5%. Results
from the SAM analysis were imported into FatiGO [11]
and Ingenuity Pathways Analysis (IPA) software (Ingenu-
ity Systems, Redwood City, CA, USA) to identify gene
ontologies that were significantly over- or under-repre-
sented. MatchMiner software [36] was used to match gene
entries between different microarray studies.
Quantitative real-time RT-PCR validation
Verification of expression of selected genes was performed
via quantitative real-time RT-PCR using the ABI Prism
7900 HT Sequence Detection System (Applied Biosys-
tems, Foster City, CA, USA) and the Universal Probe
Library System (Roche, Basel, Switzerland). Ct values were
extracted by using the SDS-software (Applied Biosys-
tems). The expression level of the housekeeping gene β-2-
microglobulin was used for normalization, calculated
with the 2-ΔΔCt method [37]. Gene expression differences
between GS 6 and GS 8-10 tumors were analyzed using t-
test. A list of examined genes including mean Ct values of
each analyzed group and corresponding primers is given
in additional file 5.
Immunohistochemical analysis
For validation of expression at the protein level, we used
immunohistochemistry (IHC) on corresponding paraffin-
embedded tissue specimens from the same patient cohort.
Immunohistochemistry was performed with 5 μm paraf-
fin tissue sections employing the Ventana Discovery - XT
staining automat (Roche). Standard CC1 pre-treatment
and antigen retrieval was followed by incubation with
antibody solution for 1 hr, choice of amplification kit,
universal antibody solution for 60 min, staining with DAPMolecular Cancer 2009, 8:130 http://www.molecular-cancer.com/content/8/1/130
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map kit and counter stain for 4 min with haematoxylin II
bluing reagent (all from Roche). For expression analysis of
MAP3K5 (ASK1) protein the mouse monoclonal antibody
EP553Y (Abcam Limited, Cambridge, MA, USA) was used
at a dilution of 1:40 for the PDIA3 protein the mouse
monoclonal antibody MaPERp571 (Abcam) at a dilution
of 1:10. Specificity of staining was controlled by including
a control antibody (DAKO Cytomation, Glostrup, Den-
mark). Immunoreactivity was then scored by a uropathol-
ogist and stratified according to the histology and the
Gleason pattern of the specimens using a 4 point scaling
system: 0, no staining, 1, weak staining, 2, intermediate
staining, 3, strong staining.
RNA interference and apoptosis assay
The human prostate cancer cell line PC3 and LNCaP were
purchased from ATCC (Manassas, VA, USA) and cultured
in RPMI 1640 or HAMs F12 medium, respectively. The
medium was supplemented with 50 units/ml penicillin,
50 μg/ml streptomycin sulphate, 1% nonessential amino
acids, and 10% FBS (all from GIBCO/BRL, Gaithersburg,
MD, USA).
PDIA3 siRNA (target sequences, see additional file 6) was
purchased from Dharmacon (Lafayette, CO, USA) and
evaluated against a scrambled siRNA control (Qiagen,
Hilden, Germany). The siRNA knockdown experiments
were performed by plating 0.8 × 104 cells PC3 cells in a 96-
well plate (NUNC, Roskilde, Denmark) overnight. For
transfection, siRNA and Lipofectamine 2000 (Invitrogen,
Carlsbad, CA, USA) were diluted separately and incubated
for 5 min at room temperature. The two solutions were
mixed and incubated for 20 min at room temperature.
siRNA-Lipofectamine 2000 mixture was then added to the
cells, and the plate was mixed by gentle rocking. Trans-
fected cells were incubated at 37°C and 5% CO2 for 48 h.
Knockdown efficiency was verified by qRT PCR.
Induction of apoptosis was performed by adding the indi-
cated amounts of Staurosporine (Roche, Mannheim, Ger-
many), Fenretinide (Sigma, Munich, Germany) or
Tapsigargin (Sigma) for 6 and 24 hours, respectively. Con-
trol cells were left untreated. Activation of apoptosis was
determined by measuring caspase 3 and 7 activities using
Caspase-Glo 3/7® Assay (Promega, Madison, WI, USA) fol-
lowing the manufacturer's protocol.
Data deposition
The microarray data sets reported in this paper have been
deposited MIAME compliant to NCBI Gene Expression
Omnibus (GEO) database (accession no. GSE15484).
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A two class unpaired SAM test with 1000 permutations was performed to 
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The False Discovery Rate (FDR) was set below 5%. Genes were assigned 
using RZPD ID, gene symbol and gene name.
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Additional file 3
Differentially expressed genes between tumors of high versus low Gleason 
score across independent datasets. Intersection of differentially expressed 
genes between high- and low risk prostate cancer with microarray data of 
True et al. 2006 [6] and Lapointe et al. 2004 [7].
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Selected genes linked to apoptosis and differentially expressed genes 
between tumors of high versus low Gleason score. Gene ontology analyses 
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apoptosis (GO:0006915, GO:0008219). Statistical data from the micro-
array experiment were included.
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